(Q36441462)

14 August 2017

1 reference

title

Rasburicase: a review of its use in the management of anticancer therapy-induced hyperuricaemia (English)

1 reference

14 August 2017

2

Caroline M Perry

1 reference

14 August 2017

Vicki Oldfield

1

1 reference

14 August 2017

1 January 2006

1 reference

14 August 2017

1 reference

14 August 2017

66

1 reference

14 August 2017

4

1 reference

14 August 2017

529-545

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200666040-00008

14 August 2017

0 references

cites work

Recombinant urate oxidase (Rasburicase) for the treatment of hyperuricemia in pediatric patients with hematologic malignancies: Results of a compassionate prospective multicenter study in Korea.

1 reference

12 December 2020

Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients With leukemia or lymphoma

1 reference

12 December 2020

Recombinant urate oxidase (rasburicase) for the prevention and treatment of tumor lysis syndrome in patients with hematologic malignancies.

1 reference

12 December 2020

Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome

1 reference

12 December 2020

Recombinant urate oxidase (rasburicase) in the prophylaxis and treatment of tumor lysis syndrome

1 reference

12 December 2020

Tumour lysis syndrome: new therapeutic strategies and classification

1 reference

12 December 2020

Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial

1 reference

12 December 2020

Managing malignancy-associated hyperuricemia with rasburicase.

1 reference

12 December 2020

Pharmacology of drugs for hyperuricemia. Mechanisms, kinetics and interactions

1 reference

12 December 2020

Incidence, medical resource utilisation and costs of hyperuricemia and tumour lysis syndrome in patients with acute leukaemia and non-Hodgkin's lymphoma in four European countries

1 reference

12 December 2020

Urate-oxidase in the prevention and treatment of metabolic complications in patients with B-cell lymphoma and leukemia, treated in the Société Française d'Oncologie Pédiatrique LMB89 protocol

1 reference

12 December 2020

Rasburicase: a potent uricolytic agent

1 reference

12 December 2020

A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis

1 reference

12 December 2020

Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte [...]

1 reference

12 December 2020

Pan-European multicentre economic evaluation of recombinant urate oxidase (rasburicase) in prevention and treatment of hyperuricaemia and tumour lysis syndrome in haematological cancer patients

1 reference

12 December 2020

Allopurinol: intravenous use for prevention and treatment of hyperuricemia

1 reference

12 December 2020

Role of i.v. allopurinol and rasburicase in tumor lysis syndrome

1 reference

12 December 2020

10.2165/00003495-200666040-00008

Identifiers

DOI

1 reference

PubMed ID

16597166

Dimensions Publication ID

14 August 2017

0 references

1 reference

PubMed ID

16597166